Children’s Cancer Institute Executive Director Michelle Haber Awarded Lemberg Medal
Children’s Cancer Institute shared a post on LinkedIn:
“We’re delighted to share that Children’s Cancer Institute Executive Director, Professor Michelle Haber AM, has received further recognition for her work, winning the prestigious Lemberg Medal.
Awarded annually by the Australian Society for Biochemistry and Molecular Biology (ASBMB), the medal recognises distinguished scientists who have demonstrated excellence in biochemistry and molecular biology and made significant contributions to the scientific community.
As well as her role as Executive Director of the Institute for the past 25 years, Michelle is also Co-Head of the Institute’s Experimental Therapeutics and Molecular Oncology Group, and Conjoint Professor at the UNSW Sydney. She is recognised internationally as a leading childhood cancer researcher, who has made pioneering breakthroughs that have greatly advanced our understanding of childhood cancer.
Through a career focussed on identifying novel targets and developing therapeutic and diagnostic approaches to improving outcomes of children with aggressive childhood malignancies, Michelle has contributed fundamental advances in knowledge and changed clinical practice, improving survival and quality of life for children with these cancers.
Michelle has pioneered three novel therapeutic approaches for high-risk child cancers (polyamine inhibition, NAMPT inhibition and chromatin modifier therapies), which have since been adopted into five national/international clinical trials.
She played a key role in developing PCR-based technology to detect minimal residual disease (MRD) in children with Acute Lymphoblastic Leukaemia (ALL), which resulted in doubling of the cure rate for high-risk patients with ALL. This led to MRD testing being made standard of care for patients with ALL, and subsequent government funding to make this test reimbursable through Medicare.
Michelle has also changed clinical practice for Australian children with cancer through her establishment and leadership of ZERO, Australia’s first child cancer personalised medicine program, which is enabling every child with cancer to have tailored therapy, targeting the specific genetic and biological characteristics of their individual tumour.
Warm congratulations to Michelle on this prestigious award.”
More posts featuring Children’s Cancer Institute.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023